Eltrombopag, a thrombopoietin mimetic, crosses the blood–brain barrier and impairs iron-dependent hippocampal neuron dendrite development

T. W. Bastian, K. A. Duck, G. C. Michalopoulos, M. J. Chen, Z. J. Liu, J. R. Connor, L. M. Lanier, M. C. Sola-Visner, M. K. Georgieff

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Essentials Potential neurodevelopmental side effects of thrombopoietin mimetics need to be considered. The effects of eltrombopag (ELT) on neuronal iron status and dendrite development were assessed. ELT crosses the blood–brain barrier and causes iron deficiency in developing neurons. ELT blunts dendrite maturation, indicating a need for more safety studies before neonatal use. Summary: Background Thrombocytopenia is common in sick neonates. Thrombopoietin mimetics (e.g. eltrombopag [ELT]) might provide an alternative therapy for selected neonates with severe and prolonged thrombocytopenia, and for infants and young children with different varieties of thrombocytopenia. However, ELT chelates intracellular iron, which may adversely affect developing organs with high metabolic requirements. Iron deficiency (ID) is particularly deleterious during brain development, impairing neuronal myelination, dopamine signaling and dendritic maturation and ultimately impairing long-term neurological function (e.g. hippocampal-dependent learning and memory). Objective To determine whether ELT crosses the blood–brain barrier (BBB), causes neuronal ID and impairs hippocampal neuron dendrite maturation. Methods ELT transport across the BBB was assessed using primary bovine brain microvascular endothelial cells. Embryonic mouse primary hippocampal neuron cultures were treated with ELT or deferoxamine (DFO, an iron chelator) from 7 days in vitro (DIV) through 14 DIV and assessed for gene expression and neuronal dendrite complexity. Results ELT crossed the BBB in a time-dependent manner. 2 and 6 μm ELT increased Tfr1 and Slc11a2 (iron-responsive genes involved in neuronal iron uptake) mRNA levels, indicating neuronal ID. 6 μm ELT, but not 2 μm ELT, decreased BdnfVI, Camk2a and Vamp1 mRNA levels, suggesting impaired neuronal development and synaptic function. Dendrite branch number and length were reduced in 6 μm ELT-treated neurons, resulting in blunted dendritic arbor complexity that was similar to DFO-treated neurons. Conclusions Eltrombopag treatment during development may impair neuronal structure as a result of neuronal ID. Preclinical in vivo studies are warranted to assess ELT safety during periods of rapid brain development.

Original languageEnglish (US)
Pages (from-to)565-574
Number of pages10
JournalJournal of Thrombosis and Haemostasis
Volume15
Issue number3
DOIs
StatePublished - Mar 1 2017

Fingerprint

Thrombopoietin
Dendrites
Iron
Neurons
Thrombocytopenia
eltrombopag
Brain
Newborn Infant
Iron Chelating Agents
Safety
Messenger RNA
Deferoxamine
Complementary Therapies
Chelating Agents

All Science Journal Classification (ASJC) codes

  • Hematology

Cite this

Bastian, T. W. ; Duck, K. A. ; Michalopoulos, G. C. ; Chen, M. J. ; Liu, Z. J. ; Connor, J. R. ; Lanier, L. M. ; Sola-Visner, M. C. ; Georgieff, M. K. / Eltrombopag, a thrombopoietin mimetic, crosses the blood–brain barrier and impairs iron-dependent hippocampal neuron dendrite development. In: Journal of Thrombosis and Haemostasis. 2017 ; Vol. 15, No. 3. pp. 565-574.
@article{33dda0ab633e4d2897391bd7d8e01a49,
title = "Eltrombopag, a thrombopoietin mimetic, crosses the blood–brain barrier and impairs iron-dependent hippocampal neuron dendrite development",
abstract = "Essentials Potential neurodevelopmental side effects of thrombopoietin mimetics need to be considered. The effects of eltrombopag (ELT) on neuronal iron status and dendrite development were assessed. ELT crosses the blood–brain barrier and causes iron deficiency in developing neurons. ELT blunts dendrite maturation, indicating a need for more safety studies before neonatal use. Summary: Background Thrombocytopenia is common in sick neonates. Thrombopoietin mimetics (e.g. eltrombopag [ELT]) might provide an alternative therapy for selected neonates with severe and prolonged thrombocytopenia, and for infants and young children with different varieties of thrombocytopenia. However, ELT chelates intracellular iron, which may adversely affect developing organs with high metabolic requirements. Iron deficiency (ID) is particularly deleterious during brain development, impairing neuronal myelination, dopamine signaling and dendritic maturation and ultimately impairing long-term neurological function (e.g. hippocampal-dependent learning and memory). Objective To determine whether ELT crosses the blood–brain barrier (BBB), causes neuronal ID and impairs hippocampal neuron dendrite maturation. Methods ELT transport across the BBB was assessed using primary bovine brain microvascular endothelial cells. Embryonic mouse primary hippocampal neuron cultures were treated with ELT or deferoxamine (DFO, an iron chelator) from 7 days in vitro (DIV) through 14 DIV and assessed for gene expression and neuronal dendrite complexity. Results ELT crossed the BBB in a time-dependent manner. 2 and 6 μm ELT increased Tfr1 and Slc11a2 (iron-responsive genes involved in neuronal iron uptake) mRNA levels, indicating neuronal ID. 6 μm ELT, but not 2 μm ELT, decreased BdnfVI, Camk2a and Vamp1 mRNA levels, suggesting impaired neuronal development and synaptic function. Dendrite branch number and length were reduced in 6 μm ELT-treated neurons, resulting in blunted dendritic arbor complexity that was similar to DFO-treated neurons. Conclusions Eltrombopag treatment during development may impair neuronal structure as a result of neuronal ID. Preclinical in vivo studies are warranted to assess ELT safety during periods of rapid brain development.",
author = "Bastian, {T. W.} and Duck, {K. A.} and Michalopoulos, {G. C.} and Chen, {M. J.} and Liu, {Z. J.} and Connor, {J. R.} and Lanier, {L. M.} and Sola-Visner, {M. C.} and Georgieff, {M. K.}",
year = "2017",
month = "3",
day = "1",
doi = "10.1111/jth.13602",
language = "English (US)",
volume = "15",
pages = "565--574",
journal = "Journal of Thrombosis and Haemostasis",
issn = "1538-7933",
publisher = "Wiley-Blackwell",
number = "3",

}

Eltrombopag, a thrombopoietin mimetic, crosses the blood–brain barrier and impairs iron-dependent hippocampal neuron dendrite development. / Bastian, T. W.; Duck, K. A.; Michalopoulos, G. C.; Chen, M. J.; Liu, Z. J.; Connor, J. R.; Lanier, L. M.; Sola-Visner, M. C.; Georgieff, M. K.

In: Journal of Thrombosis and Haemostasis, Vol. 15, No. 3, 01.03.2017, p. 565-574.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Eltrombopag, a thrombopoietin mimetic, crosses the blood–brain barrier and impairs iron-dependent hippocampal neuron dendrite development

AU - Bastian, T. W.

AU - Duck, K. A.

AU - Michalopoulos, G. C.

AU - Chen, M. J.

AU - Liu, Z. J.

AU - Connor, J. R.

AU - Lanier, L. M.

AU - Sola-Visner, M. C.

AU - Georgieff, M. K.

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Essentials Potential neurodevelopmental side effects of thrombopoietin mimetics need to be considered. The effects of eltrombopag (ELT) on neuronal iron status and dendrite development were assessed. ELT crosses the blood–brain barrier and causes iron deficiency in developing neurons. ELT blunts dendrite maturation, indicating a need for more safety studies before neonatal use. Summary: Background Thrombocytopenia is common in sick neonates. Thrombopoietin mimetics (e.g. eltrombopag [ELT]) might provide an alternative therapy for selected neonates with severe and prolonged thrombocytopenia, and for infants and young children with different varieties of thrombocytopenia. However, ELT chelates intracellular iron, which may adversely affect developing organs with high metabolic requirements. Iron deficiency (ID) is particularly deleterious during brain development, impairing neuronal myelination, dopamine signaling and dendritic maturation and ultimately impairing long-term neurological function (e.g. hippocampal-dependent learning and memory). Objective To determine whether ELT crosses the blood–brain barrier (BBB), causes neuronal ID and impairs hippocampal neuron dendrite maturation. Methods ELT transport across the BBB was assessed using primary bovine brain microvascular endothelial cells. Embryonic mouse primary hippocampal neuron cultures were treated with ELT or deferoxamine (DFO, an iron chelator) from 7 days in vitro (DIV) through 14 DIV and assessed for gene expression and neuronal dendrite complexity. Results ELT crossed the BBB in a time-dependent manner. 2 and 6 μm ELT increased Tfr1 and Slc11a2 (iron-responsive genes involved in neuronal iron uptake) mRNA levels, indicating neuronal ID. 6 μm ELT, but not 2 μm ELT, decreased BdnfVI, Camk2a and Vamp1 mRNA levels, suggesting impaired neuronal development and synaptic function. Dendrite branch number and length were reduced in 6 μm ELT-treated neurons, resulting in blunted dendritic arbor complexity that was similar to DFO-treated neurons. Conclusions Eltrombopag treatment during development may impair neuronal structure as a result of neuronal ID. Preclinical in vivo studies are warranted to assess ELT safety during periods of rapid brain development.

AB - Essentials Potential neurodevelopmental side effects of thrombopoietin mimetics need to be considered. The effects of eltrombopag (ELT) on neuronal iron status and dendrite development were assessed. ELT crosses the blood–brain barrier and causes iron deficiency in developing neurons. ELT blunts dendrite maturation, indicating a need for more safety studies before neonatal use. Summary: Background Thrombocytopenia is common in sick neonates. Thrombopoietin mimetics (e.g. eltrombopag [ELT]) might provide an alternative therapy for selected neonates with severe and prolonged thrombocytopenia, and for infants and young children with different varieties of thrombocytopenia. However, ELT chelates intracellular iron, which may adversely affect developing organs with high metabolic requirements. Iron deficiency (ID) is particularly deleterious during brain development, impairing neuronal myelination, dopamine signaling and dendritic maturation and ultimately impairing long-term neurological function (e.g. hippocampal-dependent learning and memory). Objective To determine whether ELT crosses the blood–brain barrier (BBB), causes neuronal ID and impairs hippocampal neuron dendrite maturation. Methods ELT transport across the BBB was assessed using primary bovine brain microvascular endothelial cells. Embryonic mouse primary hippocampal neuron cultures were treated with ELT or deferoxamine (DFO, an iron chelator) from 7 days in vitro (DIV) through 14 DIV and assessed for gene expression and neuronal dendrite complexity. Results ELT crossed the BBB in a time-dependent manner. 2 and 6 μm ELT increased Tfr1 and Slc11a2 (iron-responsive genes involved in neuronal iron uptake) mRNA levels, indicating neuronal ID. 6 μm ELT, but not 2 μm ELT, decreased BdnfVI, Camk2a and Vamp1 mRNA levels, suggesting impaired neuronal development and synaptic function. Dendrite branch number and length were reduced in 6 μm ELT-treated neurons, resulting in blunted dendritic arbor complexity that was similar to DFO-treated neurons. Conclusions Eltrombopag treatment during development may impair neuronal structure as a result of neuronal ID. Preclinical in vivo studies are warranted to assess ELT safety during periods of rapid brain development.

UR - http://www.scopus.com/inward/record.url?scp=85013335923&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85013335923&partnerID=8YFLogxK

U2 - 10.1111/jth.13602

DO - 10.1111/jth.13602

M3 - Article

C2 - 28005311

AN - SCOPUS:85013335923

VL - 15

SP - 565

EP - 574

JO - Journal of Thrombosis and Haemostasis

JF - Journal of Thrombosis and Haemostasis

SN - 1538-7933

IS - 3

ER -